Characterization of N-acetylcysteine (NAC) Use for the Preventions of Contrast-Induced Acute Kidney Injury (CI-AKI)
Project Description: CI-AKI is described frequently in both the inpatient and outpatient settings. Risk factors for this complication include elderly patients and those with chronic kidney disease and diabetes. Guidelines for AKI provided by the Kidney Disease Improving Global Outcomes (KDIGO) group include recommendations for the management of patients at risk for CI-AKI including using the lowest amount possible of contrast media, administering iso- or low-osmolar contrast media, and giving intravenous volume to high risk individuals. The guidelines also recommend oral NAC in conjunction with intravenous crystalloids with a strength of evidence rating of 2D. Studies offer conflicting conclusions regarding the benefit of NAC and therefore, UF Heath Shands Hospital implemented criteria for use to restrict the medication use to the highest risk individuals. Furthermore, the hospital decided to restrict the intravenous route as it is not recommended by the guidelines and is associated with a risk for an anaphylactoid reaction. This study aims to describe the adherence to the institution's restrictions and to evaluate the safety and effectiveness of this medication for this indication.
QPI: Bethany, Shoulders, (email@example.com)
Collaborators: (firstname.lastname@example.org); Martina, Holder, (email@example.com); Ginger, Gamble, (firstname.lastname@example.org)
Advisors: Bethany, Shoulders, (email@example.com)
UF Health Big Aims: Zero Harm None
MeSH Keywords: Acetylcysteine, Contrast Media, Adverse Drug Reaction Reporting Systems, Evidence-Based Medicine, Acute Kidney Injury